Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

por Voloshyna, N, Havrdová, E, Hutchinson, M, Nehrych, T, You, X, Belachew, S, Hotermans, C, Paes, D
Publicado 2015

Identification of a 48 kDa form of unconventional myosin 1c in blood serum of patients with autoimmune diseases

por Myronovkij, Severyn, Negrych, Nazar, Nehrych, Tetyana, Redowicz, Maria J., Souchelnytskyi, Serhiy, Stoika, Rostyslav, Kit, Yuriy
Publicado 2015

How Does Fingolimod (Gilenya(®)) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis?

por Fazekas, Franz, Bajenaru, Ovidiu, Berger, Thomas, Fabjan, Tanja Hojs, Ledinek, Alenka Horvat, Jakab, Gábor, Komoly, Samuel, Kobys, Tetiana, Kraus, Jörg, Kurča, Egon, Kyriakides, Theodoros, Lisý, L'ubomír, Milanov, Ivan, Nehrych, Tetyana, Moskovko, Sergii, Panayiotou, Panayiotis, Jazbec, Saša Šega, Sokolova, Larysa, Taláb, Radomír, Traykov, Latchezar, Turčáni, Peter, Vass, Karl, Vella, Norbert, Voloshyná, Nataliya, Havrdová, Eva
Publicado 2013